CAR-T cell therapy has achieved 90% complete remission rates in patients with previously untreatable acute lymphoblastic leukemia.
The engineered T-cells persist in patients for years, providing ongoing protection against cancer recurrence.
CAR-T Cell Therapy Achieves 90% Remission in Blood Cancer
Read research and analysis on CAR-T Cell Therapy Achieves 90% Remission in Blood Cancer published by ICANEWS, a global research journal for emerging researchers.
Key Takeaways
- 90% complete remission rate
- T-cells persist for years
- Previously untreatable cases respond
- Minimal long-term side effects observed
Why This Matters
CAR-T therapy represents a paradigm shift in cancer treatment from chemicals to living drugs.
Research Information
- Institution
- Peer-reviewed Journal
About ICANEWS
ICANEWS is a global research journal for emerging researchers, publishing student and emerging researcher work across all fields.